{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:56Z","timestamp":1791409856070,"version":"4.3.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560675"],"award-info":[{"award-number":["82560675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004880","name":"Xinjiang Medical University","doi-asserted-by":"publisher","award":["XYD2024GR07"],"award-info":[{"award-number":["XYD2024GR07"]}],"id":[{"id":"10.13039\/501100004880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004880","name":"Xinjiang Medical University","doi-asserted-by":"publisher","award":["X202410760033"],"award-info":[{"award-number":["X202410760033"]}],"id":[{"id":"10.13039\/501100004880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009110","name":"Natural Science Foundation of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","award":["202501A19"],"award-info":[{"award-number":["202501A19"]}],"id":[{"id":"10.13039\/100009110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110411","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:22:50Z","timestamp":1787034170000},"page":"110411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel Quinazoline-chalcone hybrids as dual VEGFR-2\/P-gp inhibitors to reverse cisplatin resistance in cervical Cancer"],"prefix":"10.1016","volume":"181","author":[{"given":"Tong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutewaer","family":"Muhebuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourboul","family":"Ablise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulipan","family":"Mulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wutiekuer","family":"Wumaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuerkaiweisaier","family":"Yalikun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110411_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1633975","article-title":"Global, regional, and national disease burden and economic costs of cervical cancer (1991-2021): a multidimensional data synthesis analysis","volume":"13","author":"Ma","year":"2025","journal-title":"Front. Public Health"},{"key":"10.1016\/j.bioorg.2026.110411_bb0010","doi-asserted-by":"crossref","unstructured":"Wilailak S, Kengsakul M, Kehoe S. Strategic approaches for global cervical cancer elimination: an update review and call for national action. Int. J. Gynaecol. Obstet. 2025; 171 Suppl 1(Suppl 1): 120\u2013128.","DOI":"10.1002\/ijgo.70276"},{"key":"10.1016\/j.bioorg.2026.110411_bb0015","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110411_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: the urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110411_bb0025","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110411_bb0030","first-page":"322","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.bioorg.2026.110411_bb0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ijgc-2022-003703","article-title":"Updates on cervical cancer prevention","volume":"33","author":"Viveros-Carre\u00f1o","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110411_bb0040","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bioorg.2026.110411_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13010092","article-title":"Advancing the fight against cervical cancer: the promise of therapeutic HPV vaccines","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.bioorg.2026.110411_bb0050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines\u00ae insights: cervical Cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.bioorg.2026.110411_bb0055","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3724\/abbs.2025032","article-title":"Long noncoding RNA UCA1 knockdown inhibits cisplatin-resistant cervical cancer tumorigenesis via the miR-195-5p\/IKBKB axis","volume":"57","author":"Wang","year":"2025","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"key":"10.1016\/j.bioorg.2026.110411_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2023.2179483","article-title":"Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?","volume":"32","author":"Vergote","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110411_bb0065","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1021\/acs.jmedchem.4c03169","article-title":"Double swords in one: novel selective PI3K\/110\u03b2 PROTAC degraders for the treatment of multidrug-resistant Cancer by activating ERS and inhibiting P-gp","volume":"68","author":"Cen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0070","doi-asserted-by":"crossref","first-page":"13909","DOI":"10.1021\/acs.jmedchem.4c00705","article-title":"Discovery of potent Isoquinolinequinone N-oxides to overcome Cancer multidrug resistance","volume":"67","author":"Kruschel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0075","doi-asserted-by":"crossref","first-page":"18764","DOI":"10.1021\/acs.jmedchem.4c01081","article-title":"Cell-based screen identifies a highly potent and orally available ABCB1 modulator for treatment of multidrug resistance","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0080","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1021\/acs.jmedchem.2c01999","article-title":"Novel benzo five-membered heterocycle derivatives as P-glycoprotein inhibitors: design, synthesis, molecular docking, and anti-multidrug resistance activity","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0085","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110411_bb0090","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1039\/D5MD00609K","article-title":"Development of heterocyclic derivatives as P-glycoprotein inhibitors against multidrug resistance: pharmacological activities, structure-activity relationship and target (2020-2024)","volume":"16","author":"Yang","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0095","doi-asserted-by":"crossref","first-page":"15248","DOI":"10.1021\/acs.joc.5c01765","article-title":"Synthetic preparation of the Macrocyclolipopeptide Dysoxylactam a for potent P-glycoprotein inhibition","volume":"90","author":"Siapkaras","year":"2025","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0100","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1021\/acs.jmedchem.3c01920","article-title":"Design and synthesis of Cyclolipopeptide mimics of Dysoxylactam a and evaluation of the reversing potencies against P-glycoprotein-mediated multidrug resistance","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0105","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1021\/acs.jmedchem.3c00283","article-title":"Discovery of Pyxinol amide derivatives bearing amino acid residues as nonsubstrate allosteric inhibitors of P-glycoprotein-mediated multidrug resistance","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2014.11.008","article-title":"P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review","volume":"6","author":"Abdallah","year":"2015","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bioorg.2026.110411_bb0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \u201cspecific\u201d P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110411_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108854","article-title":"Rational discovery of novel tetrahydroisoquinoline-indole derivatives as potent P-glycoprotein inhibitor against multidrug resistance in MCF-7\/ADR cell","volume":"164","author":"Yang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0125","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1016\/j.bmc.2014.10.032","article-title":"Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents","volume":"22","author":"Jiao","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0130","doi-asserted-by":"crossref","first-page":"14080","DOI":"10.1021\/acs.jmedchem.3c01120","article-title":"Fighting multidrug resistance with ruthenium-cyclopentadienyl compounds: unveiling the mechanism of P-gp inhibition","volume":"66","author":"Teixeira","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-4","article-title":"HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast","volume":"12","author":"Doublier","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110411_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22039","article-title":"Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1\u03b1","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.bioorg.2026.110411_bb0145","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110411_bb0150","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110411_bb0155","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1039\/D5RA01223F","article-title":"New nicotinamide-thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation","volume":"15","author":"Elgammal","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110411_bb0160","doi-asserted-by":"crossref","first-page":"145203","DOI":"10.1016\/j.molstruc.2025.145203","article-title":"Identification of novel thiazolyl-1,2,3-triazole hybrids as potent VEGFR-2 inhibitors for breast cancer treatment","volume":"1357","author":"Almatary","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110411_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005772","article-title":"High VEGFR1\/2 expression levels are predictors of poor survival in patients with cervical cancer","volume":"96","author":"Dang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bioorg.2026.110411_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113083","article-title":"Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold","volume":"211","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106735","article-title":"Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis","volume":"139","author":"Ismail","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0180","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1245\/s10434-009-0395-7","article-title":"MDR1\/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol","volume":"16","author":"Li","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.bioorg.2026.110411_bb0185","first-page":"421","article-title":"Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR-2 pathway","volume":"14","author":"Xie","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bioorg.2026.110411_bb0190","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in Cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110411_bb0195","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1039\/D5RA01280E","article-title":"Excavating medicinal virtues of chalcones to illuminate a new scope in cancer chemotherapy","volume":"15","author":"T","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110411_bb0200","first-page":"296","article-title":"Chalcones: multifunctional scaffolds bridging synthesis, structure\u2013activity relationships, and therapeutic applications: a review","volume":"8","author":"Alidmat","year":"2026","journal-title":"J Chem Rev."},{"key":"10.1016\/j.bioorg.2026.110411_bb0205","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2174\/1871520623666230223112530","article-title":"Recent progresses in Chalcone derivatives as potential anticancer agents","volume":"23","author":"Yang","year":"2023","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28237697","article-title":"Design, synthesis, and anti-cervical cancer and reversal of tumor multidrug resistance activity of novel nitrogen-containing heterocyclic chalcone derivatives","volume":"28","author":"Yang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110411_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107498","article-title":"Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives","volume":"149","author":"Yang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108639","article-title":"Design, synthesis, and in vitro and in vivo anti-drug resistant cervical cancer activity of novel licochalcone a derivatives based on dual targeting of VEGFR-2\/P-gp","volume":"163","author":"Yang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118497","article-title":"Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy","volume":"133","author":"Long","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0230","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2165\/11595310-000000000-00000","article-title":"Vandetanib: first global approval","volume":"71","author":"Commander","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110411_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106791","article-title":"New quinazoline sulfonamide derivatives as potential anticancer agents: identifying a promising hit with dual EGFR\/VEGFR-2 inhibitory and radiosensitizing activity","volume":"140","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0240","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2017.1383384","article-title":"The role of Cediranib in ovarian cancer","volume":"18","author":"Orbegoso","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110411_bb0245","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1021\/acs.jmedchem.6b01787","article-title":"Design, synthesis, and pharmacological characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H) yl) ethyl) phenyl) quinazolin-4-amine derivatives: novel inhibitors reversing P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Qiu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0250","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acs.jmedchem.1c01452","article-title":"Discovery of new 4-Indolyl Quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors","volume":"64","author":"Yuan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200027","article-title":"Overcoming multidrug resistance (MDR): design, biological evaluation and molecular modelling studies of 2,4-substituted quinazoline derivatives","volume":"17","author":"Braconi","year":"2022","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110411_bb0260","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9925919","article-title":"Apatinib induces ferroptosis of glioma cells through modulation of the VEGFR2\/Nrf2 pathway","volume":"2022","author":"Xia","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.110411_bb0265","first-page":"5620","article-title":"Sorafenib inhibited cell growth through the MEK\/ERK signaling pathway in acute promyelocytic leukemia cells","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.110411_bb0270","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/cbdd.13493","article-title":"Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation","volume":"93","author":"Wang","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.110411_bb0275","doi-asserted-by":"crossref","first-page":"E1973","DOI":"10.1073\/pnas.1717044115","article-title":"Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1","volume":"115","author":"Alam","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110411_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223678","article-title":"6-Shogaol exhibits a promoting effect with tax via binding HSP60 in non-small-cell lung cancer","volume":"11","author":"Mulati","year":"2022","journal-title":"Cells"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:05:29Z","timestamp":1791407129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"alternative-id":["S0045206826009478"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110411","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel Quinazoline-chalcone hybrids as dual VEGFR-2\/P-gp inhibitors to reverse cisplatin resistance in cervical Cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110411"}}